On August 6, Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) reported financial results for the three and six months ended June 30, and the numbers showed a company converting revenue growth into a much bigger jump in profit. Total revenue climbed 19% to $83.2 million for the quarter, but net income jumped 74% to $37.4 million, nearly four times the pace of the top line. For a biotech built almost entirely around a single approved drug, that kind of leverage is worth a closer look.
Growth That Keeps Compounding
LUPKYNIS remains the engine. Net product sales of the lupus nephritis drug rose 19% to $79.4 million for the quarter and 21% to $153 million for the six months ended June 30, up from $66.6 million and $126.5 million a year earlier. License, collaboration and royalty revenue added $3.8 million and $8.0 million over the same periods, up 12% and 36%. Aurinia reiterated its 2026 guidance of $315 million to $325 million in total revenue and $305 million to $315 million in net product sales, a sign management isn’t backing away from targets set well before the halfway point of the year.
The cash flow story backs that up. Operating cash flow rose 19% to $52.5 million for the quarter and 87% to $85.1 million for the six months, up from $44.2 million and $45.5 million a year earlier. That helped push Aurinia’s cash, equivalents, restricted cash and investments to $443.1 million at quarter end, up from $398.0 million at the end of 2025, even after repurchasing 5.0 million shares for $74.9 million. On the pipeline side, Aurinia initiated PRESERVE, a Phase 4 study combining LUPKYNIS with belimumab, obinutuzumab or anifrolumab in roughly 150 lupus nephritis patients across 50 US sites, while aritinercept, its BAFF and APRIL dual inhibitor, is now in clinical development across four potential indications.
Cracks Beneath The Numbers
The profit jump comes with caveats. Diluted earnings per share rose 75% to $0.28 for the quarter, but research and development spending nearly doubled, climbing from $7.4 million to $13.1 million in the quarter and from $13.2 million to $20.5 million over six months, as PRESERVE and aritinercept’s four programs ramp up. Income tax expense swelled even faster, from $643,000 to $11.4 million in the quarter and from $1.6 million to $20.9 million over six months, a jump that widened the gap between pretax income growth and the smaller net income figure investors actually see.
The balance sheet still carries scars from Aurinia’s pre-profitability years. The accumulated deficit stood at $577.6 million as of June 30, better than the $649.4 million at the end of 2025 but still substantial. Short-term investments fell from $317.8 million to $263.3 million, and the $74.9 million buyback, drawn from that same pool, is capital that could otherwise fund a study and four drug programs running at once. Guidance, notably, was reiterated rather than raised despite a quarter that outpaced it.
What The Market Is Pricing
Hedge fund ownership in Aurinia held flat at 28 funds quarter over quarter, showing neither accumulation nor an exit. Short interest sits at 7.45% of the float, a level that points to a real but not overwhelming bear camp. The stock trades at a forward P/E of 11.57, as of September 15, a multiple more typical of a mature pharmaceutical name than a company posting double-digit revenue growth and a 74% jump in quarterly net income. That gap between the growth rate and the multiple is the tension sitting underneath the unchanged fund count.
A Story Still Being Written
Aurinia’s second quarter told a fairly simple story: a single approved drug generating enough cash to fund a broader pipeline while still returning capital to shareholders. LUPKYNIS’s growth, PRESERVE’s launch and aritinercept’s four-indication expansion give the case that this is no longer a one-drug company. But rising R&D costs, a heavier tax bill and a still-sizable accumulated deficit are reminders that the path to durable profitability isn’t finished.
READ NEXT: 10 Best Future Stocks to Buy Under $10 and 12 Best Performing Semiconductor Stocks to Invest In.
